331 related articles for article (PubMed ID: 31583083)
1. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology.
Eran Z; Zingariello M; Bochicchio MT; Bardelli C; Migliaccio AR
F1000Res; 2019; 8():. PubMed ID: 31583083
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Zahr AA; Salama ME; Carreau N; Tremblay D; Verstovsek S; Mesa R; Hoffman R; Mascarenhas J
Haematologica; 2016 Jun; 101(6):660-71. PubMed ID: 27252511
[TBL] [Abstract][Full Text] [Related]
4. TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche.
Yao JC; Oetjen KA; Wang T; Xu H; Abou-Ezzi G; Krambs JR; Uttarwar S; Duncavage EJ; Link DC
J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35439167
[TBL] [Abstract][Full Text] [Related]
5. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
Guy A; Bidet A; Ling C; Caumont C; Boureau L; Viallard JF; Parrens M
Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
[TBL] [Abstract][Full Text] [Related]
6. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
Pizzi M; Gergis U; Chaviano F; Orazi A
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
[TBL] [Abstract][Full Text] [Related]
7. Novel targets to cure primary myelofibrosis from studies on Gata1
Zingariello M; Martelli F; Verachi P; Bardelli C; Gobbo F; Mazzarini M; Migliaccio AR
IUBMB Life; 2020 Jan; 72(1):131-141. PubMed ID: 31749302
[TBL] [Abstract][Full Text] [Related]
8. [Myelofibrosis: A review].
Genthon A; Killian M; Mertz P; Cathebras P; Gimenez De Mestral S; Guyotat D; Chalayer E
Rev Med Interne; 2021 Feb; 42(2):101-109. PubMed ID: 33243417
[TBL] [Abstract][Full Text] [Related]
9. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
[TBL] [Abstract][Full Text] [Related]
11. Application of Stem Cell Therapy in Myelofibrosis.
Davidson MB; Gupta V
Hematol Oncol Clin North Am; 2021 Apr; 35(2):391-407. PubMed ID: 33641876
[TBL] [Abstract][Full Text] [Related]
12. Biology and management of idiopathic myelofibrosis.
Smith BD; Moliterno AR
Curr Opin Oncol; 2001 Mar; 13(2):91-4. PubMed ID: 11224705
[TBL] [Abstract][Full Text] [Related]
13. Allogenic hematopoietic stem cell as curative treatment in myelofibrosis.
Wardhana ; Datau EA; Rotty LW; Haroen H
Acta Med Indones; 2011 Oct; 43(4):252-9. PubMed ID: 22156358
[TBL] [Abstract][Full Text] [Related]
14. Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.
Hart C; Klatt S; Barop J; Müller G; Schelker R; Holler E; Huber E; Herr W; Grassinger J
Haematologica; 2016 Nov; 101(11):1407-1416. PubMed ID: 27662011
[TBL] [Abstract][Full Text] [Related]
15. Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis.
Kapor S; Momčilović S; Kapor S; Mojsilović S; Radojković M; Apostolović M; Filipović B; Gotić M; Čokić V; Santibanez JF
Adv Exp Med Biol; 2023; 1408():273-290. PubMed ID: 37093433
[TBL] [Abstract][Full Text] [Related]
16. Primary myelofibrosis and its targeted therapy.
Shantzer L; Berger K; Pu JJ
Ann Hematol; 2017 Apr; 96(4):531-535. PubMed ID: 27539616
[TBL] [Abstract][Full Text] [Related]
17. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
Alchalby H; Kröger N
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
[TBL] [Abstract][Full Text] [Related]
19. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
Morsia E; Gangat N
Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
[No Abstract] [Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.
Kekre N; Ho VT
Am J Hematol; 2016 Jan; 91(1):123-30. PubMed ID: 26453238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]